2019 Future of Binge Eating Disorder R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Binge Eating Disorder treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Binge Eating Disorder pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Binge Eating Disorder pipeline companies from advancing their products into Phase 3 or Phase 4.
Binge Eating Disorder Report Description-
The 2019 pipeline study on Binge Eating Disorder pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Binge Eating Disorder pipeline compounds.
The Binge Eating Disorder pipeline guide presents information on all active drugs currently being developed for Binge Eating Disorder. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Binge Eating Disorder pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Binge Eating Disorder drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Binge Eating Disorder product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Binge Eating Disorder pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Binge Eating Disorder pipeline report includes-
Binge Eating Disorder Report Description-
The 2019 pipeline study on Binge Eating Disorder pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Binge Eating Disorder pipeline compounds.
The Binge Eating Disorder pipeline guide presents information on all active drugs currently being developed for Binge Eating Disorder. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Binge Eating Disorder pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Binge Eating Disorder drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Binge Eating Disorder product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Binge Eating Disorder pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Binge Eating Disorder pipeline report includes-
- An overview of Binge Eating Disorder disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Binge Eating Disorder pipeline
- Company wise list of Binge Eating Disorder pipeline
- Mechanism of Action wise Binge Eating Disorder pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Binge Eating Disorder pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Binge Eating Disorder pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Binge Eating Disorder pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL BINGE EATING DISORDER PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Binge Eating Disorder Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Binge Eating Disorder pipeline, H1- 2019
3.5 Mechanism of Action wise Binge Eating Disorder Pipeline Candidates
4 AMYGDALA NEUROSCIENCES INC BINGE EATING DISORDER PIPELINE DETAILS
4.1 Amygdala Neurosciences Inc Business Profile
4.2 Amygdala Neurosciences Inc Binge Eating Disorder Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 CHRONOS THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS
5.1 Chronos Therapeutics Ltd Business Profile
5.2 Chronos Therapeutics Ltd Binge Eating Disorder Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 F. HOFFMANN-LA ROCHE LTD BINGE EATING DISORDER PIPELINE DETAILS
6.1 F. Hoffmann-La Roche Ltd Business Profile
6.2 F. Hoffmann-La Roche Ltd Binge Eating Disorder Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 HEPTARES THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS
7.1 Heptares Therapeutics Ltd Business Profile
7.2 Heptares Therapeutics Ltd Binge Eating Disorder Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 NOVO NORDISK AS BINGE EATING DISORDER PIPELINE DETAILS
8.1 Novo Nordisk AS Business Profile
8.2 Novo Nordisk AS Binge Eating Disorder Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 OMEROS CORP BINGE EATING DISORDER PIPELINE DETAILS
9.1 Omeros Corp Business Profile
9.2 Omeros Corp Binge Eating Disorder Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 OPIANT PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS
10.1 Opiant Pharmaceuticals Inc Business Profile
10.2 Opiant Pharmaceuticals Inc Binge Eating Disorder Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 SEROPEUTICS LLC BINGE EATING DISORDER PIPELINE DETAILS
11.1 Seropeutics LLC Business Profile
11.2 Seropeutics LLC Binge Eating Disorder Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 SUNOVION PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS
12.1 Sunovion Pharmaceuticals Inc Business Profile
12.2 Sunovion Pharmaceuticals Inc Binge Eating Disorder Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 TAKEDA PHARMACEUTICAL CO LTD BINGE EATING DISORDER PIPELINE DETAILS
13.1 Takeda Pharmaceutical Co Ltd Business Profile
13.2 Takeda Pharmaceutical Co Ltd Binge Eating Disorder Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. LATEST BINGE EATING DISORDER DRUG PIPELINE DEVELOPMENTS, 2019
15. APPENDIX
15.1 About Us
15.2 Sources and Methodology
15.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL BINGE EATING DISORDER PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Binge Eating Disorder Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Binge Eating Disorder pipeline, H1- 2019
3.5 Mechanism of Action wise Binge Eating Disorder Pipeline Candidates
4 AMYGDALA NEUROSCIENCES INC BINGE EATING DISORDER PIPELINE DETAILS
4.1 Amygdala Neurosciences Inc Business Profile
4.2 Amygdala Neurosciences Inc Binge Eating Disorder Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 CHRONOS THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS
5.1 Chronos Therapeutics Ltd Business Profile
5.2 Chronos Therapeutics Ltd Binge Eating Disorder Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 F. HOFFMANN-LA ROCHE LTD BINGE EATING DISORDER PIPELINE DETAILS
6.1 F. Hoffmann-La Roche Ltd Business Profile
6.2 F. Hoffmann-La Roche Ltd Binge Eating Disorder Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 HEPTARES THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS
7.1 Heptares Therapeutics Ltd Business Profile
7.2 Heptares Therapeutics Ltd Binge Eating Disorder Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 NOVO NORDISK AS BINGE EATING DISORDER PIPELINE DETAILS
8.1 Novo Nordisk AS Business Profile
8.2 Novo Nordisk AS Binge Eating Disorder Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 OMEROS CORP BINGE EATING DISORDER PIPELINE DETAILS
9.1 Omeros Corp Business Profile
9.2 Omeros Corp Binge Eating Disorder Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 OPIANT PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS
10.1 Opiant Pharmaceuticals Inc Business Profile
10.2 Opiant Pharmaceuticals Inc Binge Eating Disorder Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 SEROPEUTICS LLC BINGE EATING DISORDER PIPELINE DETAILS
11.1 Seropeutics LLC Business Profile
11.2 Seropeutics LLC Binge Eating Disorder Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 SUNOVION PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS
12.1 Sunovion Pharmaceuticals Inc Business Profile
12.2 Sunovion Pharmaceuticals Inc Binge Eating Disorder Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 TAKEDA PHARMACEUTICAL CO LTD BINGE EATING DISORDER PIPELINE DETAILS
13.1 Takeda Pharmaceutical Co Ltd Business Profile
13.2 Takeda Pharmaceutical Co Ltd Binge Eating Disorder Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. LATEST BINGE EATING DISORDER DRUG PIPELINE DEVELOPMENTS, 2019
15. APPENDIX
15.1 About Us
15.2 Sources and Methodology
15.3 Contact Information
